SORT BY

FILTER BY

also on other fortune lists

company facts

f500 stats

Fortune 500

Gerald Abel—Bass Photo Co.

132

Eli Lilly

LLY

The pharmaceutical giant manufactures drugs for humans as well as for livestock and poultry.

Looking for leads, investment insights, or competitive intelligence?

CEO

David A. Ricks

CEO Title

President, Chief Executive Officer & Director

Sector

Health Care

Industry

Pharmaceuticals

HQ Location

Indianapolis, IN

Years on Fortune 500 List

23

Employees

41,975

Profile provided by S&P Global.
Eli Lilly is also featured in these fortune lists
Key Financials (Last Fiscal Year)
$ millions% change
Revenues ($M)$21,2226.3%
Profits ($M)$2,737.613.7%
Assets ($M)$38,806
Total Stockholder Equity ($M)$14,007.7
Market Value — as of March 31, 2017 ($M)$92,803
Profit Ratios
Profit as % of Revenues12.9%
Profits as % of Assets7.1%
Profits as % of Stockholder Equity19.5%
Earnings Per Share (Last Fiscal Year)
Earnings Per Share ($)2.58
EPS % Change (from 2015)14.2%
EPS % Change (5 year annual rate)-7.9%
EPS % Change (10 year annual rate)0.5%
Total Return
Total Return to Investors (2016)-10.2%
Total Return to Investors (5 year, annualized)15.9%
Total Return to Investors (10 year, annualized)7.8%
STOCK QUOTE
()0.00 0.00 (0)
  • Previous Close:
  • Market Cap: NaNB
  • Next Earnings Date:
  • High:
  • Low:
  • 52 Week High:
  • 52 Week Low:
  • 52 Week Change %: 0.00
  • P/E Ratio: n/a
  • EPS:
  • Dividend Yield: n/a

News about Eli Lilly

Could a New Immunotherapy Medical Approach Break the Alzheimer's Drug Curse?

AbbVie and Alector hope to apply immunotherapy to dementia and Alzheimer's.

Read More →
Goldman Sachs Bet on Biogen's Potential Landmark Alzheimer's Drug Props Up Stock

Goldman analysts think the drug could eventually ring in $12 billion in sales if approved.

Read More →
Valeant's New CEO Joe Papa Has a $17 Billion Ultimatum

If he pulls it off, he will make more than all of his peers combined.

Read More →